These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20028770)

  • 1. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.
    Galimberti F; Thompson SL; Liu X; Li H; Memoli V; Green SR; DiRenzo J; Greninger P; Sharma SV; Settleman J; Compton DA; Dmitrovsky E
    Clin Cancer Res; 2010 Jan; 16(1):109-20. PubMed ID: 20028770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.
    Danilov AV; Hu S; Orr B; Godek K; Mustachio LM; Sekula D; Liu X; Kawakami M; Johnson FM; Compton DA; Freemantle SJ; Dmitrovsky E
    Mol Cancer Ther; 2016 Nov; 15(11):2758-2766. PubMed ID: 27550941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.
    Kawakami M; Mustachio LM; Rodriguez-Canales J; Mino B; Roszik J; Tong P; Wang J; Lee JJ; Myung JH; Heymach JV; Johnson FM; Hong S; Zheng L; Hu S; Villalobos PA; Behrens C; Wistuba I; Freemantle S; Liu X; Dmitrovsky E
    J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28376145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110.
    Hu S; Danilov AV; Godek K; Orr B; Tafe LJ; Rodriguez-Canales J; Behrens C; Mino B; Moran CA; Memoli VA; Mustachio LM; Galimberti F; Ravi S; DeCastro A; Lu Y; Sekula D; Andrew AS; Wistuba II; Freemantle S; Compton DA; Dmitrovsky E
    Cancer Res; 2015 May; 75(10):2029-38. PubMed ID: 25808870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown.
    Hu S; Lu Y; Orr B; Godek K; Mustachio LM; Kawakami M; Sekula D; Compton DA; Freemantle S; Dmitrovsky E
    Mol Cancer Ther; 2015 Nov; 14(11):2576-85. PubMed ID: 26304236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting low molecular weight cyclin E (LMW-E) in breast cancer.
    Nanos-Webb A; Jabbour NA; Multani AS; Wingate H; Oumata N; Galons H; Joseph B; Meijer L; Hunt KK; Keyomarsi K
    Breast Cancer Res Treat; 2012 Apr; 132(2):575-88. PubMed ID: 21695458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death.
    Josefsberg Ben-Yehoshua L; Beider K; Shimoni A; Ostrovsky O; Samookh M; Peled A; Nagler A
    PLoS One; 2012; 7(4):e33856. PubMed ID: 22558078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
    Coley HM; Shotton CF; Kokkinos MI; Thomas H
    Gynecol Oncol; 2007 May; 105(2):462-9. PubMed ID: 17300833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers.
    Kawakami M; Mustachio LM; Chen Y; Chen Z; Liu X; Wei CH; Roszik J; Kittai AS; Danilov AV; Zhang X; Fang B; Wang J; Heymach JV; Tyutyunyk-Massey L; Freemantle SJ; Kurie JM; Liu X; Dmitrovsky E
    Mol Cancer Ther; 2021 Mar; 20(3):477-489. PubMed ID: 33277443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.
    Whittaker SR; Te Poele RH; Chan F; Linardopoulos S; Walton MI; Garrett MD; Workman P
    Cell Cycle; 2007 Dec; 6(24):3114-31. PubMed ID: 18075315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents.
    Fleming IN; Hogben M; Frame S; McClue SJ; Green SR
    Clin Cancer Res; 2008 Jul; 14(13):4326-35. PubMed ID: 18594016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
    Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
    Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
    Raje N; Kumar S; Hideshima T; Roccaro A; Ishitsuka K; Yasui H; Shiraishi N; Chauhan D; Munshi NC; Green SR; Anderson KC
    Blood; 2005 Aug; 106(3):1042-7. PubMed ID: 15827128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor.
    Iurisci I; Filipski E; Reinhardt J; Bach S; Gianella-Borradori A; Iacobelli S; Meijer L; Lévi F
    Cancer Res; 2006 Nov; 66(22):10720-8. PubMed ID: 17108108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance.
    Khalil HS; Mitev V; Vlaykova T; Cavicchi L; Zhelev N
    J Biotechnol; 2015 May; 202():40-9. PubMed ID: 25747275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seliciclib in malignancies.
    Aldoss IT; Tashi T; Ganti AK
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1957-65. PubMed ID: 19938906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E.
    Akli S; Van Pelt CS; Bui T; Meijer L; Keyomarsi K
    Cancer Res; 2011 May; 71(9):3377-86. PubMed ID: 21385896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma.
    Cheng CK; Gustafson WC; Charron E; Houseman BT; Zunder E; Goga A; Gray NS; Pollok B; Oakes SA; James CD; Shokat KM; Weiss WA; Fan QW
    Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12722-7. PubMed ID: 22802621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine.
    Bettayeb K; Sallam H; Ferandin Y; Popowycz F; Fournet G; Hassan M; Echalier A; Bernard P; Endicott J; Joseph B; Meijer L
    Mol Cancer Ther; 2008 Sep; 7(9):2713-24. PubMed ID: 18790752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
    Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
    PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.